Research programme: cardio and neuroprotective cyclophilin inhibitors - NeuroVive/Isomerase Therapeutics

Drug Profile

Research programme: cardio and neuroprotective cyclophilin inhibitors - NeuroVive/Isomerase Therapeutics

Alternative Names: NCCIM; Non-Ciclosporin Cyclophilin Inhibiting Molecules; NVP 019; Sangamides - NeuroVive

Latest Information Update: 09 May 2014

Price : $50

At a glance

  • Originator Biotica Technology
  • Developer Isomerase Therapeutics; NeuroVive Pharmaceutical
  • Class Macrolides; Neuroprotectants
  • Mechanism of Action Cyclophilin D inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Brain injuries; Cardiovascular disorders

Most Recent Events

  • 08 Jan 2014 Preclinical trials in Brain injuries (as a neuroprotectant) in Sweden (IV)
  • 08 Jan 2014 Preclinical trials in Cardiovascular disorders (prevention of relapse) in Sweden (IV)
  • 12 Jun 2013 NeuroVive Pharmaceutical and Isomerase Therapeutics enter into a collaboration to develop and commercialise cyclophilin inhibitors
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top